SEC Form 4 · accession 0001882764-26-000005
Enliven Therapeutics, Inc. · ELVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Hohl
Officer — CHIEF FINANCIAL OFFICER
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 5:13 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001672619
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 17, 2026 | M | 6,018 | $2.48 | A | 57,018 | D | |
| Common StockF3,F2 | Jun 17, 2026 | S | 1,379 | $42.785 | D | 55,639 | D | |
| Common StockF4,F2 | Jun 17, 2026 | S | 3,401 | $43.8634 | D | 52,238 | D | |
| Common StockF5,F2 | Jun 17, 2026 | S | 1,238 | $44.7475 | D | 51,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $2.48 | Jun 17, 2026 | M | 6,018 | D | — | Aug 2, 2031 | Common Stock | 6,018 | 86,038 | D |
Explanation of responses
- F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
- F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F3This transaction was executed in multiple trades at prices ranging from $42.295 to $43.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4This transaction was executed in multiple trades at prices ranging from $43.3342 to $44.3142. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5This transaction was executed in multiple trades at prices ranging from $44.3548 to $44.945. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6All of the shares subject to this option are fully vested and exercisable as of the date hereof.